Quince Therapeutics, Inc.
QNCX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$56,828 | -$31,385 | -$51,660 | -$89,945 |
| Dep. & Amort. | $186 | $322 | $204 | $344 |
| Deferred Tax | $0 | -$248 | -$284 | $878 |
| Stock-Based Comp. | $4,746 | $5,220 | $16,618 | $29,853 |
| Change in WC | -$484 | $1,977 | -$9,829 | -$4,261 |
| Other Non-Cash | $20,476 | $5,822 | $913 | $199 |
| Operating Cash Flow | -$31,904 | -$18,292 | -$44,038 | -$62,932 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$257 | -$160 | -$133 | -$180 |
| Net Acquisitions | $0 | -$2,116 | $10,593 | -$58,952 |
| Inv. Purchases | -$89,562 | -$113,781 | -$75,021 | -$38,789 |
| Inv. Sales/Matur. | $109,379 | $111,209 | $82,493 | $97,921 |
| Other Inv. Act. | $2,348 | -$910 | $70 | $58,952 |
| Investing Cash Flow | $21,908 | -$5,758 | $18,002 | $58,952 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | -$6 | -$49 | $0 |
| Stock Issued | $225 | $149 | $608 | $6,808 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$5,000 | $0 | $148 | $0 |
| Financing Cash Flow | -$4,775 | $143 | $707 | $6,808 |
| Forex Effect | $231 | $80 | $184 | $55 |
| Net Chg. in Cash | -$14,540 | -$23,827 | -$25,145 | $2,883 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $20,752 | $44,579 | $69,724 | $66,841 |
| End Cash | $6,212 | $20,752 | $44,579 | $69,724 |
| Free Cash Flow | -$32,161 | -$18,452 | -$44,171 | -$63,112 |